CCN2 and systemic sclerosis: Type I IFNs in SSc have multiple supported effects including the activation of monocytes, the differentiation and activation of T lymphocytes, B lymphocytes, and dendritic cells, stimulation of the expression of Toll-like receptors by dendritic cells, and increasing the expression of fibrotic effectors such as CTGF and ACTA in endothelial cells and fibroblasts, amongst others (53).